Clinical trials: Breast Cancer, Breast Neoplasms
Breast Neoplasm, Triple Negative Breast Cancer (TNBC)
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patient allocation via minimisation (cohorts A-D) or allocation according to HRD and…
- Conditions
- Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD
- Trial name
- PHOENIX (NCT03740893)
- Testing
- AZD6738, Olaparib, Durvalumab
- Where
- 6 sites in United Kingdom
- Volunteers
- 119 people
- Sponsor
- Institute of Cancer Research, United Kingdom
TNBC - Triple-Negative Breast Cancer, TNBC
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
This is an open-label, Simon's optimal two-stage design, single-arm, Phase II study with first 6 patients in the safety run-in portion.
- Trial name
- NCT07441512
- Testing
- Inavolisib in Combination With Eribulin
- Volunteers
- 26 people
- Sponsor
- Hu Hai
Artifical Inteligence, Cardiology
Safe and Explainable AI
While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of patient and disease management.
- Conditions
- Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
- Trial name
- NCT06694181
- Testing
- AI-PERSONALIZED CLINICAL DECISION SUPPORT
- Where
- United States
- Volunteers
- 300,000 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer.
- Conditions
- Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer
- Trial name
- NCT02874430
- Testing
- Metformin Hydrochloride, Doxycycline
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Neoplasms
Clinical Exploratory Study on Predicting Drug Sensitivity for Breast Cancer Treatment Using Simulated Organoid Models.
In this trial, we plan to construct a patient-derived organoid (PDO) model using fresh tumor tissue samples. Taking the relevant data of drug efficacy of breast cancer organoids as an example, it is shown that organoids may…
- Trial name
- NCT06702800
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiangya Hospital of Central South University
Breast Cancer
A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females
This two-part study is designed to select the subcutaneous (SC) dose of Herceptin that results in comparable exposure to intravenous (IV) Herceptin in healthy male participants and in HER2-positive female participants.
- Trial name
- NCT00800436
- Testing
- Herceptin
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)
ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort
This Vietnam-based observational study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor…
- Conditions
- HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer
- Trial name
- NCT07808164
- Testing
- IHC analysis for ENPP1, cGAS, and FAP expression
- Where
- 2 sites in Vietnam
- Volunteers
- 162 people
- Sponsor
- Tam Anh Research Institute
Invasive Ductal Carcinoma, Breast
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer
This study will investigate the safety, feasibility, and immune response associated with cryoablation of early invasive breast cancer prior to lumpectomy.
- Trial name
- NCT03523299
- Testing
- Cryoablation
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Neoplasms, Fertility
Fertility Preservation in Breast Cancer Patients
The purpose of this study is to evaluate efficiency and safety of controlled ovarian stimulation (COS) associated with an aromatase inhibitor (letrozole) for fertility preservation in breast cancer patients.
- Trial name
- Brovale (NCT02661932)
- Testing
- Letrozole
- Where
- Belgium
- Volunteers
- 65 people
- Sponsor
- Erasme University Hospital
Breast Cancer
Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive
Drains are routinely utilized in breast reconstruction when using abdominal tissue of the patient to remove fluid buildup while the body heals after surgery.
- Trial name
- NCT03159598
- Testing
- Tissue Glu, Drain, Questionnaires
- Sponsor
- Case Comprehensive Cancer Center
Lymphedema
Strength Training Intervention for Breast Cancer Survivors and the Effects on Lymphedema Status
The purpose of the PAL trial is to increase the understanding of the experiences of long-term breast cancer survivors. Study hypothesis: Strength training will not increase the rate of lymphedema or worsen lymphedema as compared…
- Trial name
- NCT00194363
- Testing
- Strength training
- Where
- United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer Invasive
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer
This study aims to explore the diagnostic performance of [18F]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with ER-positive breast cancer having clinically suspected or confirmed axillary lymph node…
- Trial name
- NCT06695039
- Testing
- Fluoroestradiol (18F)
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Asan Medical Center
Metastatic Breast Cancer
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to identify the highest tolerable dose of pyrotinib in combination with vinorelbine and to assess the safety and efficacy of the combination in Patients With HER2-Positive Locally Advanced or…
- Trial name
- NCT03997539
- Testing
- Pyrotinib, Treatment of physician's choice, vinorelbine
- Volunteers
- 256 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
SuPr Study (Supine Versus Prone Treatment Position in Breast Radiotherapy)
A randomised, two-arm, non-blinded crossover study investigating the impact of treatment position (prone versus supine) upon reproducibility of tumour bed position in patients undergoing breast radiotherapy following excision of…
- Trial name
- SuPr (NCT01001728)
- Testing
- Imaging investigations (with radiation)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Breast Cancer
Rapid Medical Donation Programme for Breast Cancer
Treatment of breast cancer has traditionally been based on the primary tumour's features in the breast. Only recently, when cancer returns at other sites, has there been an attempt to biopsy the metastatic disease and change…
- Trial name
- LEGACY (NCT02126800)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
The aim of the study is to evaluate the objective response rate (ORR) of single agent lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non amplified with 11q amplification, or FGFR1-non amplified without…
- Trial name
- FINESSE (NCT02053636)
- Testing
- lucitanib
- Where
- 29 sites in Australia, Belgium and 7 more
- Volunteers
- 76 people
- Sponsor
- Institut de Recherches Internationales Servier
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer, Gemcitabine
Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer
The primary purpose of our study is to evaluate whether gemcitabine as a single agent is superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who achieved disease…
- Conditions
- Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer, Gemcitabine, Maintenance Chemotherapy
- Trial name
- NCT02188693
- Where
- China
- Volunteers
- 267 people
- Sponsor
- Xijing Hospital
Breast Cancer
Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer
Breast cancer is the most frequent malignancy in women. Standard therapy for early-stage breast cancer is breast conserving surgery (BCS) followed by adjuvant whole breast irradiation (WBI), which usually requires a treatment…
- Trial name
- COSMOPOLITAN (NCT03838419)
- Testing
- intraoperative radiotherapy, whole breast irradiation
- Where
- Germany
- Volunteers
- 101 people
- Sponsor
- University Hospital Heidelberg
Stage IV Breast Cancer, Recurrent Breast Cancer
Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Antineoplastons are naturally occurring substances that may also be made in the laboratory.
- Trial name
- NCT00003536
- Testing
- antineoplaston A10, methotrexate, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Metastatic Breast Cancer
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Letrozole is an aromatase inhibitor that is approved in the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
- Trial name
- NCT00634634
- Testing
- Sorafenib, Letrozole
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Rutgers, The State University of New Jersey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.